Switch theme
Sign up to access all valuation multiples
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
1937
17.3K+
LTM Revenue $4.6B
LTM EBITDA $1.1B
$15.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Smith & Nephew has a last 12-month revenue (LTM) of $4.6B and a last 12-month EBITDA of $1.1B.
In the most recent fiscal year, Smith & Nephew achieved revenue of $7.8B and an EBITDA of $1.6B.
Smith & Nephew expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Smith & Nephew valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.6B | XXX | $7.8B | XXX | XXX | XXX |
| Gross Profit | $3.2B | XXX | $5.4B | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $1.1B | XXX | $1.6B | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $817M | XXX | $1.2B | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $601M | XXX | $553M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Smith & Nephew's stock price is GBP 11 (or $14).
Smith & Nephew has current market cap of GBP 9.4B (or $12.6B), and EV of GBP 11.4B (or $15.3B).
See Smith & Nephew trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.3B | $12.6B | XXX | XXX | XXX | XXX | $0.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Smith & Nephew has market cap of $12.6B and EV of $15.3B.
Smith & Nephew's trades at 2.0x EV/Revenue multiple, and 9.3x EV/EBITDA.
Equity research analysts estimate Smith & Nephew's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Smith & Nephew has a P/E ratio of 15.6x.
See valuation multiples for Smith & Nephew and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.6B | XXX | $12.6B | XXX | XXX | XXX |
| EV (current) | $15.3B | XXX | $15.3B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 9.9x | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBIT | 13.9x | XXX | 13.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.6x | XXX | 22.7x | XXX | XXX | XXX |
| EV/FCF | 23.6x | XXX | 18.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSmith & Nephew's last 12 month revenue growth is 1%
Smith & Nephew's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Smith & Nephew's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Smith & Nephew's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Smith & Nephew and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | -9% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Smith & Nephew acquired XXX companies to date.
Last acquisition by Smith & Nephew was XXXXXXXX, XXXXX XXXXX XXXXXX . Smith & Nephew acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Smith & Nephew founded? | Smith & Nephew was founded in 1937. |
| Where is Smith & Nephew headquartered? | Smith & Nephew is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Smith & Nephew have? | As of today, Smith & Nephew has 17.3K+ employees. |
| Who is the CEO of Smith & Nephew? | Smith & Nephew's CEO is Mr. Deepak S. Nath. |
| Is Smith & Nephew publicy listed? | Yes, Smith & Nephew is a public company listed on LON. |
| What is the stock symbol of Smith & Nephew? | Smith & Nephew trades under SN. ticker. |
| When did Smith & Nephew go public? | Smith & Nephew went public in 1951. |
| Who are competitors of Smith & Nephew? | Similar companies to Smith & Nephew include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Smith & Nephew? | Smith & Nephew's current market cap is $12.6B |
| What is the current revenue of Smith & Nephew? | Smith & Nephew's last 12 months revenue is $4.6B. |
| What is the current revenue growth of Smith & Nephew? | Smith & Nephew revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Smith & Nephew? | Current revenue multiple of Smith & Nephew is 2.5x. |
| Is Smith & Nephew profitable? | Yes, Smith & Nephew is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Smith & Nephew? | Smith & Nephew's last 12 months EBITDA is $1.1B. |
| What is Smith & Nephew's EBITDA margin? | Smith & Nephew's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Smith & Nephew? | Current EBITDA multiple of Smith & Nephew is 9.9x. |
| What is the current FCF of Smith & Nephew? | Smith & Nephew's last 12 months FCF is $482M. |
| What is Smith & Nephew's FCF margin? | Smith & Nephew's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Smith & Nephew? | Current FCF multiple of Smith & Nephew is 23.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
